Estimating prognosis of patients with liver disease based on blood parameters

Assessment of lymphocyte monocyte ratio in predicting severe disease among hospitalised patients with liver cirrhosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Observational

Source

CTRI

Registry ID

CTRI/2021/09/036283

Enrollment

120

Registered

2021-09-07

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K740- Hepatic fibrosis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: All patients aged >= 18 years admitted at Kasturba Hospital with the confirmed diagnosis of liver cirrhosis of any underlying etiology will be included in the study.

Exclusion criteria

Exclusion criteria: Patients aged Co-existence of hepatocellular carcinoma or other malignant tumour Patients with haematological malignancy and autoimmune disease Patients with acquired immunodeficiency syndrome Patients presenting with any kind of infections such as tuberculosis will also excluded from the study.

Design outcomes

Primary

Measure	Time frame
Lymphocte monocyte ratio as an independent, cost effective tools to predict severity of disease in liver cirrhosis patients.Timepoint: 1 YEAR	—

Secondary

Measure	Time frame
LMR as an independent indicator in inflammatory diseasesTimepoint: 1 YEAR	—

Countries

India

Contacts

Public ContactISHITA GUPTA

KASTURBA HOSPITAL, MAHE MANIPAL

shekar.uk@manipal.edu9845163448

Outcome results